Project Data Sphere

See the following -

Big Pharma Companies Open Up Cancer Trial Comparator Arm Data

Nick Paul Taylor | Fierce Biotech IT | April 11, 2014

A lot has changed in clinical trial transparency since Project Data Sphere outlined plans to share cancer results in 2012, with the European law voted in last week then still a distant threat. Even so, Pfizer ($PFE), Sanofi ($SNY) and the other groups behind the initiative think it still offers something different now that it has belatedly launched.

Read More »

Research Symbiosis Makes Mathematical Crystal Ball to Gaze into Future of Prostate Cancer Treatment

Press Release | University of Colorado Cancer Center | August 4, 2017

The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. These patients may have been better off with another treatment in the first place, but who’s to know before trying the drug which patients will go on to experience debilitating side effects? A crowdsourced competition asked this as an open question. Today in the Journal of Clinical Oncology Clinical Cancer Informatics, competition organizers and participating teams report their findings...

Read More »

Winners Announced for Crowdsourcing and Data Sharing Competition to Drive Innovation in Prostate Cancer Research

Press Release | Sage Bionetworks, Project Data Sphere Initiative, DREAM Challenges Initiative | August 27, 2015

Industry leaders in biomedical research, oncology data sharing and computational science announced the winners of an innovative research challenge for prostate cancer using previously unavailable clinical data. The Prostate Cancer DREAM Challenge is the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes. The Challenge called upon the cancer research and computational biology community to find solutions to key open clinical research questions about mCRPC and explore innovative research and modeling approaches. The three specific questions posed were to: